These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8638818)

  • 1. Procoagulant action of aprotinin.
    Alston TA
    Anesth Analg; 1996 Jun; 82(6):1305-6. PubMed ID: 8638818
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of the anticoagulant properties of aprotinin in vitro.
    Mortier E; Ongenae M; Van Aken J; Den Blauwen N; Rolly G
    Eur J Anaesthesiol; 1996 Sep; 13(5):468-70. PubMed ID: 8889419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of aprotinin on heparinized whole blood activated clotting time and whole blood prothrombin time].
    Wen Z; Zhu F; He X; Xiong S; He S
    Hunan Yi Ke Da Xue Xue Bao; 1997; 22(4):304-6. PubMed ID: 9868081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of aprotinin on thrombelastography in vitro.
    Chalkiadis GA; Gibbs NM
    Anaesth Intensive Care; 1996 Oct; 24(5):552-4. PubMed ID: 8909664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the anticoagulant action of aprotinin ("trasylol").
    Prentice CR; Mcnicol GP; Macnicol GP; Douglas AS
    Thromb Diath Haemorrh; 1970 Oct; 24(1):265-72. PubMed ID: 5312434
    [No Abstract]   [Full Text] [Related]  

  • 6. Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro.
    Despotis GJ; Filos KS; Levine V; Alsoufiev A; Spitznagel E
    Anesth Analg; 1996 Jun; 82(6):1126-31. PubMed ID: 8638779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrinsic pathway--associated activated clotting time for anticoagulation monitoring during cardiopulmonary bypass.
    Gu YJ; Huyzen RJ; van Oeveren W
    Anesth Analg; 1996 Aug; 83(2):433. PubMed ID: 8694335
    [No Abstract]   [Full Text] [Related]  

  • 8. The in vitro effects of aprotinin on twelve different ACT tests.
    Jones K; Nasrallah F; Darling E; Clay N; Searles B
    J Extra Corpor Technol; 2004 Mar; 36(1):51-7. PubMed ID: 15095841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue factor-induced coagulation can be inhibited by aprotinin (Trasylol).
    van den Besselaar AM; Dirven R; Bertina RM
    Thromb Haemost; 1993 Mar; 69(3):298-9. PubMed ID: 7682341
    [No Abstract]   [Full Text] [Related]  

  • 10. [Haemostatic action of approtinin of Czechoslovak provenience, Antilysin Spofa, in rats subjected to whole-body irradiation (author's transl)].
    Pospísil J; Poucková P; Klír P; Dienstbier Z
    Sb Lek; 1979; 81(11-12):349-57. PubMed ID: 316170
    [No Abstract]   [Full Text] [Related]  

  • 11. Aprotinin inhibits thrombin formation and monocyte tissue factor in simulated cardiopulmonary bypass.
    Khan MM; Gikakis N; Miyamoto S; Rao AK; Cooper SL; Edmunds LH; Colman RW
    Ann Thorac Surg; 1999 Aug; 68(2):473-8. PubMed ID: 10475415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of coagulation and fibrinolysis by aromatic amidino compounds. An in vitro and in vivo study.
    Geratz JD
    Thromb Diath Haemorrh; 1971 Jun; 25(3):391-404. PubMed ID: 5314899
    [No Abstract]   [Full Text] [Related]  

  • 13. [Inhibition of the thromboplastic activity of amniotic fluid with Trasylol].
    Slunsky R
    Gynakol Rundsch; 1973; 13(2):147-52. PubMed ID: 4542664
    [No Abstract]   [Full Text] [Related]  

  • 14. Hemostatic defect in baboons autotransfused treated plasma to simulate shed blood.
    Valeri CR; Morse DS; Ragno G; Dennis RC
    J Card Surg; 2006; 21(6):565-71. PubMed ID: 17073954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive model for the humoral coagulation network in humans.
    Wajima T; Isbister GK; Duffull SB
    Clin Pharmacol Ther; 2009 Sep; 86(3):290-8. PubMed ID: 19516255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelial-related coagulation in pediatric surgery.
    Boldt J
    Ann Thorac Surg; 1998 Jun; 65(6 Suppl):S56-9; discussion S74-6. PubMed ID: 9647140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo reversal of the anticoagulant effects of edoxaban.
    Halim AB; Samama MM; Mendell J
    Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban.
    Gerotziafas GT; Baccouche H; Sassi M; Galea V; Chaari M; Hatmi M; Samama MM; Elalamy I
    Thromb Res; 2012 Jan; 129(1):101-3. PubMed ID: 22000405
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices.
    Dalbert S; Ganter MT; Furrer L; Klaghofer R; Zollinger A; Hofer CK
    Acta Anaesthesiol Scand; 2006 Apr; 50(4):461-8. PubMed ID: 16548858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose dependent effect of aprotinin on rate of clot formation.
    De Hert SG; Farooqi NU; Delrue GL; Broecke PW; Vermeyen KM; Adriaensen HF
    Eur J Anaesthesiol; 1996 Sep; 13(5):463-7. PubMed ID: 8889418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.